Leslie is a neuropsychologist with over 20 years of experience in academia, pharmaceutical and biotech neuroscience research. She is the VP of Medical Science at Ovid Therapeutics. She, along with her fellow Ovidians, are dedicated to developing medicines that significantly impact the lives of patients with rare neurological disorders.
Leslie started her pharmaceutical career in clinical development. She has led Phase 1 through 4 clinical development programs across a wide range of CNS conditions including schizophrenia, bipolar disorder, traumatic brain injury and Alzheimer’s disease. While at MGH in the Department of Psychiatry, Leslie was the Program Director for the first public health study of bipolar disorder, the Systematic Treatment Enhance Program for Bipolar Disorder (STEP-BD). Leslie holds a PhD from the University of Pittsburgh, where she also completed her post doc in adult and pediatric epilepsy. Her research interests in CNS are guided by the vision and passion of bringing innovative treatments to patients